Morphological spectrum of immune check‐point inhibitor therapy‐associated gastritis
Johncilla M, Grover S, Zhang X, Jain D, Srivastava A. Morphological spectrum of immune check‐point inhibitor therapy‐associated gastritis. Histopathology 2020, 76: 531-539. PMID: 31692018, DOI: 10.1111/his.14029.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalFemaleGastritisHumansIpilimumabMaleMiddle AgedNeoplasmsNivolumabConceptsImmune check-point inhibitor therapyCheck-point inhibitor therapyImmune-related adverse eventsImmune check point inhibitorsMorphological spectrumIntra-epithelial lymphocytosisCheck point inhibitorsChronic active gastritisInflammatory bowel diseaseMedical chart reviewCytotoxic T cellsDrug-induced gastritisPredominant histological patternDistribution of injuriesVariety of tumorsMechanism of actionSteroid therapyGastrointestinal injuryActive gastritisAdverse eventsChart reviewClinical suspicionMedication withdrawalBowel diseaseInhibitor therapy